Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Bites and Stings, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma in Situ, Uterine Cervical Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Skin Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Triple Negative Breast Neoplasms

NCT04154943 2025-12-23

Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

Phase 2 Completed

79 enrolled 16 charts

Dermatologic

Cutaneous Squamous Cell Carcinoma

NCT06413680 2025-12-15

BrILliance

Phase 1/2 Recruiting

240 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

NCT06132191 2025-11-20

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Approved for marketing

DermatologicThoracic

Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung

NCT06052852 2025-11-17

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Phase 1 Terminated

17 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03836105 2025-10-15

CASE

Completed

287 enrolled

Dermatologic

Carcinoma, Basal Cell

NCT03969004 2025-09-19

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Phase 3 Active not recruiting

415 enrolled 1 FDA

Dermatologic

Cutaneous Squamous Cell Carcinoma

NCT05259696 2025-08-20

GLIMMER-01

Phase 1/2 Completed

69 enrolled 13 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05608291 2025-05-13

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Phase 3 Active not recruiting

1,564 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT03132636 2025-04-08

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Phase 2 Completed

138 enrolled 21 charts 1 FDA

Dermatologic

Carcinoma, Basal Cell

NCT04291105 2025-03-26

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Phase 2 Recruiting

87 enrolled

DermatologicGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Melanoma

NCT06090266 2025-01-07

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Phase 1/2 Recruiting

168 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neoplasms

NCT05094804 2023-11-02

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Phase 1/2 Unknown

172 enrolled

DermatologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Leiomyosarcoma, Liposarcoma, Melanoma, Neoplasm Metastasis, Neoplasms

NCT03684785 2022-04-07

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

Phase 1/2 Terminated

57 enrolled

Dermatologic

Melanoma, Skin Neoplasms, Carcinoma, Merkel Cell

NCT02423863 2020-12-17

Poly-ICLC

Phase 2 Completed

26 enrolled

DermatologicHead & NeckSarcoma

Head and Neck Neoplasms, Melanoma, Neoplasms, Sarcoma

NCT03002376 2020-04-20

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)

Phase 1 Completed

47 enrolled

Dermatologic

Melanoma

Clinical Trials

ANCHOR

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

ON-5001

Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

BrILliance

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

CASE

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

GLIMMER-01

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

Poly-ICLC

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)